Rigvir Virotherapy treatment has been used on a wide variety of cancers including melanoma, stomach cancer, colorectal cancer, pancreatic cancer, kidney cancer, uterine cancer, bladder cancer, lung cancer, prostate cancer, and several types of sarcoma.
Virotherapy is theorized to be an effective cancer treatment that uses oncotropic and oncolytic virus with the ability of a virus to find and destroy malignant cells in the body. Rigvir contains a live nonpathogenic ECHO-7 virus that has not been genetically modified. It finds and selectively infects tumor cells. Then replicates in tumor cells and destroys them. Both of these processes — oncotropism and oncolysis — are selective for tumor cells and normal healthy cells are minimally affected, if at all.
Rigvir is an oncolytic, nonpathogenic ECHO-7 virus that significantly prolongs survival in early-stage melanoma patients without any side effects. 
The ECHO-7 virus can be found naturally in the intestines of healthy young children. This virus co-exists with other micro-organisms in the intestines without causing any side effects. This means that patients can make use of Rigvir Virotherapy for long periods of time without adverse side effects. In fact, doctors have noted that Rigvir seems to actually strengthen the immune system and help the body naturally prevent the growth of cancerous cells.
ECHO-7 is one of a number of viruses that are oncotropic, which means that they migrate selectively to cancer cells. The virus enters and then multiplies within these cancer cells through a process called oncolysis, which destroys them. At the same time, the virus makes the cancer cells visible to the body's immune system. Many tumors develop the ability to mask themselves from the immune system, which is why the body is unable to fight off cancer cells. This problem is overcome through the direct ability of Rigvir to target and kill cancer cells, combined with its indirect ability to revive the body's immune response to cancer.
Pharmaceutical companies are trying to develop virotherapy-based anti-cancer candidates. However, their therapies are based on pathogenic viruses that cause diseases such as HIV-AIDS, herpes, polio, measles, and influenza. The viruses are genetically altered to remove their pathogenicity, with unknown long-term consequences.
Clinical studies conducted with Rigvir in Latvia by Dr. Aina Muceniece have suggested it to be 3-4 times better when compared to selected immunotherapies. Patients experienced a 5-year survival rate of 75 percent for melanoma with metastasis to the lymph node and 53 percent for patients with more invasive melanoma that has penetrated 4 millimeters or more into the skin. Stage II melanoma patients demonstrated a 4-6 fold lower mortality rate compared to those under observation who did not receive Rigvir.
Since the introduction of Rigvir Virotherapy at the Hope4Cancer Institute, 91 percent of patients, many with advanced Stage IV cancer, have reported a sustained or improved quality of life with a high expectancy of greatly improving their chances of survival.
- Doniņa S, Strēle I, Proboka G, Auziņš J, Alberts P, Jonsson B, Venskus D, Muceniece A. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015 Oct;25(5):421-6. doi: 10.1097/CMR.0000000000000180. PubMed PMID: 26193376; PubMed Central PMCID: PMC4560272.